Evidence map›Paper›PMID 34590151›Full record

ArticleMolecular medicine reports2021

CMBs carrying PTX and CRISPR/Cas9 targeting

Siyuan Peng, Junhong Cai, Shan Bao

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Endometriosis: Future Biological Perspectives for Diagnosis and Treatment.International journal of molecular sciences · 2024
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Siyuan Peng *Department of Gynaecology and Obstetrics, Hainan Hospital Affiliated to University of South China, Haikou, Hainan 570311, P.R. China.
Junhong Cai *Key Laboratory of Cell and Molecular Genetic Translational Medicine in Hainan Province, Hainan General Hospital, Haikou, Hainan 570311, P.R. China.
Shan BaoDepartment of Gynaecology and Obstetrics, Hainan General Hospital/Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, P.R. China.
Hainan General Hospital · CNHainan Medical University · CNUniversity of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of combination therapy to decrease side effects of chemotherapeutic drugs and increase their utilization rate in combination with gene editing is a key research topic in tumor treatment. The present study aimed to investigate the effect of cationic microbubbles (CMBs) carrying paclitaxel (PTX) and

Indexed as

Antineoplastic Agents, PhytogenicCell Line, TumorCell ProliferationCRISPR-Cas SystemsCyclin-Dependent Kinase Inhibitor p21Disease ProgressionDrug TherapyEndometrial NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleGene EditingGene Expression Regulation, NeoplasticGene Knockout TechniquesHumansMicrobubblesPaclitaxelAntineoplastic Agents, PhytogenicCyclin-Dependent Kinase Inhibitor p21ERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasesp27 antigenPaclitaxelProliferating Cell Nuclear Antigenchemotherapy drugchemotherapy‑gene combination therapygene editingtumor therapyultrasound cationic microbubbles

Identifiers

PMID34590151
PMCPMC8503745
OpenAlexW3204689854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.